Enzolytics Inc. Announces Collaboration with Abveris to Discover Monoclonal Antibodies
Enzolytics, Inc. (ENZC) has announced a collaboration with Abveris, a subsidiary of Twist Bioscience, to expedite the discovery of fully human monoclonal antibodies aimed at various viruses, focusing initially on SARS-CoV-2. This partnership will leverage Abveris' advanced immunization techniques and Enzolytics' AI platform to enhance antibody development. The goal is to produce effective therapies for both human and veterinary applications, utilizing antibodies from convalescent individuals. The collaboration is expected to significantly accelerate Enzolytics' antibody portfolio expansion.
- Collaboration with Abveris enhances antibody discovery capabilities.
- Focus on fully human monoclonal antibodies reduces chances of ineffective treatment due to viral mutations.
- Dependence on timely execution of studies for effective outcomes.
- Risks associated with the accuracy of forward-looking statements.
COLLEGE STATION, TX / ACCESSWIRE / September 16, 2022 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company").
Enzolytics, Inc. announces a collaboration with Abveris, a division of Twist Bioscience Corporation, to discover fully human monoclonal antibodies against multiple viruses. Abveris applies advanced immunization methods combined with B cell screening and hybridoma-based antibody discovery technologies to provide comprehensive gene-to-antibody discovery services.
The collaboration makes possible the combination of the synergistic technologies of the two companies in discovering monoclonal antibodies against numerous pathogenic viruses. Under the terms of the collaboration, Abveris (also known as Twist Boston) will utilize human patient donor peripheral blood mononuclear cell (PBMC) samples and peptide screening tools provided by Enzolytics to perform rapid B cell screening and identify antigen-binding antibodies for further characterization by Enzolytics. The companies will initially focus on discovering antibodies targeting SARS-CoV-2.
Enzolytics' focus is on producing fully human monoclonal antibodies targeting multiple viral infectious diseases, including SARS-CoV-2, HIV-1, Feline Leukemia virus, and Feline Immunodeficiency virus. The Company's antibodies are produced from human "immune-B cells" obtained from convalescent individuals who have recovered from the target virus. The Company's Artificial Intelligence (AI) platform is used to identify highly conserved, immutable target sites on viruses. Production of antibodies targeting these conserved sites on the viruses will result in the production of antibodies that are not rendered ineffective by virus mutation. These fully human monoclonal antibodies have the original antibody affinity and specificity and minimized chances of immunogenicity.
This collaboration allows Enzolytics to significantly expedite the production of monoclonal antibodies against the numerous human and animal viruses which Enzolytics has analyzed using its AI platform.
"We have been impressed by Abveris' track record of discovering and delivering therapeutic antibodies," said Dr. Gaurav Chandra, Chief Operating Officer of Enzolytics. "To efficiently block COVID-19 infections and transmission, we need to get high levels of secretory IgA, reflecting mucosal immunity. Abveris will identify promising monoclonal antibody candidates via function-forward, high-resolution screening under expedited timelines.
This partnership with Abveris complements our efforts to significantly expand our antibody portfolio. We look forward to collaborating with Abveris to move us closer to our goal of expediently developing therapies for both human and veterinary use."
Safe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Enzolytics, Inc. from time to time in its periodic reports filed with the SEC.
While Enzolytics, Inc. believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Enzolytics to establish the efficacy of its therapeutics in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of its therapeutics in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate.
Such forward-looking statements are based on current expectations. They involve inherent risks and uncertainties, including factors that could delay, divert or change any of the statements made, and cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. These forward-looking statements are made as of the date of this press release. The Company expressly disclaims any intention or obligation to update the forward-looking statements or update the reasons why actual results could differ from those projected in the forward-looking statements.
Company Contact:
Enzolytics, Inc.
www.enzolytics.com
info@enzolytics.com
Texas A&M Institute for Preclinical Studies
800 Raymond Stotzer Parkway
College Station, Texas 77843-4478
SOURCE: Enzolytics, Inc.
View source version on accesswire.com:
https://www.accesswire.com/716224/Enzolytics-Inc-Announces-Collaboration-with-Abveris-to-Discover-Monoclonal-Antibodies
FAQ
What is the collaboration between Enzolytics and Abveris about?
How will the collaboration impact Enzolytics' stock (ENZC)?
What diseases are targeted by the monoclonal antibodies developed by Enzolytics?
What technologies are involved in this collaboration?
When was the collaboration between Enzolytics and Abveris announced?
